Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Contribution of 3D Modeling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors

NCT06418243 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-09-16
Last updated
2026-09-10

Condition(s) studied

Pelvic TumorRetroperitoneal Tumor

Study summary

This study's purpose is the comparison of the automatically segmented 3D model to the reference manual segmentation, based on the Dice precision index. It is implemented by making parents' patients, surgeons and surgical helpers answer specific questions comparing 3D images to usual 2D images of the patient's tumor.

Eligibility

Sex
ALL
Min age
3 Months
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: Children: * Children between 3 months and less than 18 years old * Children with a pelvic tumor requiring an MRI for a possible surgical intervention * Children with a retroperitoneal tumor requiring a CT scan or MRI with a view to surgical intervention * Children with no contraindication for a CT scan and/or 3T MRI * Children whose parents do not object to their participation in the study Other participants: * Operating surgeon agreeing to participate in the study * Caregiver agreeing to participate in the study * External surgeon agreeing to participate in the study Exclusion Criteria: Children : * Contraindication to MRI: metallic ocular foreign body, pacemaker, mechanical heart valve, old vascular clips on cerebral aneurysm * Need for an MRI under general anaesthesia * Contraindication for a CT scan with injection: renal failure, allergy to iodinated contrast products * Patients having participated in a therapeutic clinical trial involving a new molecule within 30 days before inclusion * Emergency situation

Primary outcome measure(s)

  • Segmentation comparison — 1 month
    Comparison of the automatically segmented 3D model to the reference manual segmentation, based on the Dice precision index

Trial sites (1)

FacilityCityRegionStatus
Hôpital Necker Enfants Malades. Service de Chirurgie Viscérale et Urologie pédiatrique Paris Île-de-France Region Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06418243 on ClinicalTrials.gov ↗ ← All trials in France